Clinical Trial Update: First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sacituzumab govitecan as first-line therapy in adults with advanced untreated triple-negative breast cancer; the study is not yet rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Nathalie Levasseur | Conditions: Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic | Phase 2 | Status: NOT_YET_RECRUITING